open access

Vol 65, No 1 (2015)
Research paper (original)
Published online: 2015-03-06
Get Citation

Survival of patients treated with radiation for non-small-cell lung cancer in Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii in Olsztyn between 2003 and 2006

Karolina Osowiecka, Monika Rucińska, Andrzej Każarnowicz, Sergiusz Nawrocki
DOI: 10.5603/NJO.2015.0003
·
Nowotwory. Journal of Oncology 2015;65(1):14-22.

open access

Vol 65, No 1 (2015)
Original article
Published online: 2015-03-06

Abstract

Introduction. In Poland lung cancer has a very poor prognosis and it is the most common cause of cancer deaths. Our aim was to study survival analysis of patients treated for non-small-cell lung cancer (NSCLC) in Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii in Olsztyn between 2003 and 2006 (the initial 4 years of Centre activity).

Material and methods. The analysis included all patients (801) treated with radiation for NSCLC between 2003 and 2006 (I–IV clinical stages, treated with radical or palliative radiotherapy).

Results. Overall 2-year and 5-year survival (OS) of all patients was 19% and 7% (median 7 months). Two-year and five­-year OS of patients treated with radical intent was 43% and 18% (median 1 year and 9 months). There was a trend for better prognosis in women (p = 0.075). There was no significant influence of clinical stage, tumour size, histopatholo­gy, radiotherapy dose (≤ 60 Gy versus > 60 Gy) or duration of chemoradiotherapy on survival in chemoradiotherapy group (p > 0.05). The only statistically significant factor was lymph node involvement: N0 versus N2 (p = 0.017) and N1 versus N2 (p = 0.008).

Conclusions. There was no statistically significant influence of sex, clinical stage, tumour size, histopathology, dose and duration of chemoradiotherapy on OS. The only statistically significant factor was lymph node involvement.

Abstract

Introduction. In Poland lung cancer has a very poor prognosis and it is the most common cause of cancer deaths. Our aim was to study survival analysis of patients treated for non-small-cell lung cancer (NSCLC) in Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii in Olsztyn between 2003 and 2006 (the initial 4 years of Centre activity).

Material and methods. The analysis included all patients (801) treated with radiation for NSCLC between 2003 and 2006 (I–IV clinical stages, treated with radical or palliative radiotherapy).

Results. Overall 2-year and 5-year survival (OS) of all patients was 19% and 7% (median 7 months). Two-year and five­-year OS of patients treated with radical intent was 43% and 18% (median 1 year and 9 months). There was a trend for better prognosis in women (p = 0.075). There was no significant influence of clinical stage, tumour size, histopatholo­gy, radiotherapy dose (≤ 60 Gy versus > 60 Gy) or duration of chemoradiotherapy on survival in chemoradiotherapy group (p > 0.05). The only statistically significant factor was lymph node involvement: N0 versus N2 (p = 0.017) and N1 versus N2 (p = 0.008).

Conclusions. There was no statistically significant influence of sex, clinical stage, tumour size, histopathology, dose and duration of chemoradiotherapy on OS. The only statistically significant factor was lymph node involvement.

Get Citation
About this article
Title

Survival of patients treated with radiation for non-small-cell lung cancer in Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii in Olsztyn between 2003 and 2006

Journal

Nowotwory. Journal of Oncology

Issue

Vol 65, No 1 (2015)

Article type

Research paper (original)

Pages

14-22

Published online

2015-03-06

DOI

10.5603/NJO.2015.0003

Bibliographic record

Nowotwory. Journal of Oncology 2015;65(1):14-22.

Authors

Karolina Osowiecka
Monika Rucińska
Andrzej Każarnowicz
Sergiusz Nawrocki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl